JP2011041578A5 - - Google Patents

Download PDF

Info

Publication number
JP2011041578A5
JP2011041578A5 JP2010257738A JP2010257738A JP2011041578A5 JP 2011041578 A5 JP2011041578 A5 JP 2011041578A5 JP 2010257738 A JP2010257738 A JP 2010257738A JP 2010257738 A JP2010257738 A JP 2010257738A JP 2011041578 A5 JP2011041578 A5 JP 2011041578A5
Authority
JP
Japan
Prior art keywords
dosage unit
expression vector
alvac
preparation according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010257738A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011041578A (ja
JP5373747B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011041578A publication Critical patent/JP2011041578A/ja
Publication of JP2011041578A5 publication Critical patent/JP2011041578A5/ja
Application granted granted Critical
Publication of JP5373747B2 publication Critical patent/JP5373747B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010257738A 2003-09-05 2010-11-18 黒色腫用の多抗原ベクター Expired - Fee Related JP5373747B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50057203P 2003-09-05 2003-09-05
US60/500,572 2003-09-05
US50400703P 2003-09-18 2003-09-18
US60/504,007 2003-09-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006525474A Division JP2007503834A (ja) 2003-09-05 2004-09-03 黒色腫用の多抗原ベクター

Publications (3)

Publication Number Publication Date
JP2011041578A JP2011041578A (ja) 2011-03-03
JP2011041578A5 true JP2011041578A5 (OSRAM) 2012-10-11
JP5373747B2 JP5373747B2 (ja) 2013-12-18

Family

ID=34316448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006525474A Pending JP2007503834A (ja) 2003-09-05 2004-09-03 黒色腫用の多抗原ベクター
JP2010257738A Expired - Fee Related JP5373747B2 (ja) 2003-09-05 2010-11-18 黒色腫用の多抗原ベクター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006525474A Pending JP2007503834A (ja) 2003-09-05 2004-09-03 黒色腫用の多抗原ベクター

Country Status (9)

Country Link
US (1) US8911991B2 (OSRAM)
EP (1) EP1660119A2 (OSRAM)
JP (2) JP2007503834A (OSRAM)
KR (1) KR101141951B1 (OSRAM)
AU (2) AU2004273034A1 (OSRAM)
BR (1) BRPI0413334A (OSRAM)
CA (1) CA2537931A1 (OSRAM)
IL (1) IL173637A0 (OSRAM)
WO (1) WO2005026370A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US20060217893A1 (en) * 2005-01-07 2006-09-28 Yanbin Li Method for detecting an unknown contaminant concentration in a substance
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
WO2008028124A1 (en) * 2006-09-01 2008-03-06 The Board Of Trustees Of The University Of Arkansas Methods and systems for detection of contaminants
WO2009042773A1 (en) * 2007-09-25 2009-04-02 University Of Miami Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons
WO2011140284A2 (en) * 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
TWI733719B (zh) 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
WO2018094309A2 (en) 2016-11-21 2018-05-24 Nant Holdings Ip, Llc Fractal combination therapy
EP4052255B1 (en) 2019-11-18 2024-10-09 Google LLC Privacy-aware meeting room transcription from audio-visual stream

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6770456B1 (en) * 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
JP4409097B2 (ja) * 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
AU1013601A (en) * 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CA2412050C (en) * 2000-06-15 2011-03-22 Jeffrey Schlom A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
AU2002239363A1 (en) * 2000-11-28 2002-06-11 Wyeth Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
AU2003228339A1 (en) * 2002-03-20 2003-10-08 Aventis Pasteur, Inc. Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003095642A2 (en) * 2002-05-07 2003-11-20 Aventis Pasteur, Ltd. Polyepitopes and mini-genes for cancer treatment

Similar Documents

Publication Publication Date Title
Gómez et al. Clinical applications of attenuated MVA poxvirus strain
BR112015009320A2 (pt) promotor pr13.5 para respostas de células t e anticorpo robustas
WO2014144885A3 (en) Cancer vaccines and methods of treatment using the same
ECSP17084137A (es) Neoantígenos compartidos
JP2012524075A5 (OSRAM)
JP2012021028A5 (OSRAM)
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
JP2016074727A5 (OSRAM)
MX377144B (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
JP2015529676A5 (OSRAM)
PE20081875A1 (es) Procedimiento novedoso y composiciones
JP2016510989A5 (OSRAM)
PH12018502403A1 (en) Hiv vaccine formulation
Kim et al. Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
JP2015533376A5 (OSRAM)
JP2016508999A5 (OSRAM)
AU2002347317A1 (en) Vaccine
JP2010523138A5 (OSRAM)
JP2014530627A5 (OSRAM)
AR053275A1 (es) Composicion de vacuna
JP2014533938A5 (OSRAM)
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
JP2014139185A5 (OSRAM)